Technology
eClinical Solutions Market to Grow by USD 12.77 Billion (2024-2028), Rising Drug Clinical Trials Drive Revenue, Report Highlights AI Impact on Trends – Technavio
Published
2 years agoon
By
NEW YORK, Dec. 5, 2024 /PRNewswire/ — Report on how AI is redefining market landscape – The global eclinical solutions market size is estimated to grow by USD 12.77 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 15.26% during the forecast period. Rise in clinical trials for drugs is driving market growth, with a trend towards increasing outsourcing of clinical trial processes. However, rising cost of clinical trials poses a challenge. Key market players include Advarra Inc., Aixial, Anju Software Inc., ArisGlobal LLC, Castor Research Inc., Dassault Systemes SE, DATATRAK International Inc., eClinical Solutions LLC., eClinicalWorks LLC, eResearchTechnology GmbH, International Business Machines Corp., MedNet, Medrio Inc., OpenClinica LLC, Oracle Corp., Parexel International Corp., Saama Technologies Inc., Signant Health, Veeva Systems Inc., and YPrime LLC.
AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF
Forecast period
2024-2028
Base Year
2023
Historic Data
2018 – 2022
Segment Covered
End-user (Pharmaceutical and biotechnology companies, Contract research organizations, Consulting service companies, Medical device manufacturers, and Others), Deployment (Cloud-based and On-premises), and Geography (North America, Europe, Asia, and Rest of World (ROW))
Region Covered
North America, Europe, Asia, and Rest of World (ROW)
Key companies profiled
Advarra Inc., Aixial, Anju Software Inc., ArisGlobal LLC, Castor Research Inc., Dassault Systemes SE, DATATRAK International Inc., eClinical Solutions LLC., eClinicalWorks LLC, eResearchTechnology GmbH, International Business Machines Corp., MedNet, Medrio Inc., OpenClinica LLC, Oracle Corp., Parexel International Corp., Saama Technologies Inc., Signant Health, Veeva Systems Inc., and YPrime LLC
Key Market Trends Fueling Growth
The eClinical solutions market is experiencing significant growth due to the increasing emphasis on clinical trials and vaccine development for various chronic diseases such as cancer, cardiovascular conditions, and infectious diseases. The enormous data generated during these trials requires advanced software solutions for clinical data management (CDM) and clinical trial management systems (CTMS). EClinical solutions like Veeva Systems and PAREXE are gaining popularity due to their benefits of real-time access, error reduction, and cost efficiency. The rising number of clinical trials and observational studies, coupled with research funding, is driving the adoption of eClinical solutions. However, the lack of awareness and high costs are challenges for smaller enterprises and underdeveloped markets. The digitization of healthcare through the Internet of Things and information technologies is also influencing the market. Firms like TRIO and CROs are focusing on clinical randomization, supply management, and site performance to improve drug development and retention. Healthcare engineering, clinical researchers, and healthcare providers are also integrating eClinical solutions into their clinical trial processes, leading to growth opportunities for eClinical solution providers. The market is characterized by a firm concentration ratio, with major players like Veeva Systems and PAREXE dominating. The market also includes academic universities, hospitals, research centers, and process outsourcing firms. The development of medical devices and IT infrastructure, such as EDC, CDMS, and web-hosted or cloud-based clinical trials, are also contributing to the market’s growth. Consultancy services and licenced enterprise solutions are also available to support the market.
The eClinical Solutions Market has witnessed significant changes in the past decade, with a shift towards outsourcing drug discovery processes to subcontract laboratories. This trend is driven by increased R&D investments and the focus on core competencies in manufacturing and marketing. Since 2011, the number of subcontract laboratories has grown rapidly, and this trend is expected to continue. The industry has transformed from a vertical reporting model with in-house clinical study teams to a matrix model involving both external and internal resources. Gradually, the bulk of the work has moved to Contract Research Organizations (CROs). This outsourcing trend enables companies to reduce costs, improve efficiency, and focus on their core competencies.
Insights on how AI is driving innovation, efficiency, and market growth- Request Sample!
• The eClinical solutions market is experiencing significant growth due to the increasing emphasis on clinical trials and vaccine development for unmet medical needs in healthcare. The rising number of clinical trials for chronic diseases such as cancer, cardiovascular conditions, and infectious diseases, requires enormous data management. EClinical solutions like Veeva Systems and TRIO are addressing these challenges by providing software solutions for clinical data management (CDM), clinical trial management systems (CTMS), and clinical randomization. However, there are challenges such as high costs, lack of awareness, and integration issues with various systems like CDM, clinical research organizations (CROs), academic universities, hospitals, and research centers. The digitization of healthcare through the Internet of Things and information technologies is driving the need for data standardization and real-time access to clinical trial data. Smaller enterprises and developing markets face challenges in technology adoption due to the high costs and lack of internet connectivity. However, the benefits of eClinical solutions like cost efficiency, site performance, and error reduction make them an attractive option for clinical researchers and healthcare providers. Firms with a high firm concentration ratio, such as pharmaceutical companies and medical device manufacturers, are investing in eClinical solutions for clinical trial processes, supply management, and protocol matrices. Consultancy services like PAREXE are providing expertise in clinical trial processes and regulatory compliance to help firms navigate the complex clinical trial landscape. The growth opportunities in this market are vast, with a particular focus on clinical trial processes, drug development, and clinical research.
• Clinical trials are a crucial part of bringing new drugs to market, but their cost has become a significant concern. Factors contributing to this increase include the complex and lengthy process of patient enrolment and retention. According to recent studies, the cost per patient in clinical trials rose by over 150% in the US between 2010 and 2015, and by 85-90% in the UK during the same period. These figures underscore the need for effective clinical trial management solutions to streamline processes, improve patient engagement, and reduce costs.
Insights into how AI is reshaping industries and driving growth- Download a Sample Report
This eclinical solutions market report extensively covers market segmentation by
End-user 1.1 Pharmaceutical and biotechnology companies1.2 Contract research organizations1.3 Consulting service companies1.4 Medical device manufacturers1.5 OthersDeployment 2.1 Cloud-based2.2 On-premisesGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)
1.1 Pharmaceutical and biotechnology companies- Clinical trials are a crucial part of the drug development process for pharmaceutical and biotechnology companies. The success of these trials is essential for bringing new treatments to market. However, clinical trials are lengthy and expensive, and failures can result in significant financial and time losses. Regulatory scrutiny and the need for high-quality data have led to the increased adoption of eClinical solutions, such as Clinical Trial Management Systems (CTMS), among these companies. Mundipharma Research, a pharmaceutical research and development company, and GlaxoSmithKline, one of the largest pharmaceutical companies, are among those that have implemented eClinical solutions to enhance the efficiency and control of their clinical trials. These web-based systems provide real-time access to trial information, faster decision-making, decreased trial costs, and increased employee productivity and job satisfaction. With the rise in the number of clinical trials due to the increasing number of diseases and advanced treatments in development, the demand for eClinical solutions is on the rise. These solutions help companies manage the complexities of clinical trials, ensuring regulatory compliance, data accuracy, and operational efficiency. The market for eClinical solutions is expected to grow significantly during the forecast period as more companies recognize the benefits of these technologies in bringing new treatments to market.
Download complimentary Sample Report to gain insights into AI’s impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 – 2022)
The eClinical solutions market is experiencing significant growth due to the enormous data generated from clinical trials in healthcare. The rising number of clinical trials and emphasis on eClinical solutions for research is driving the market forward. Software solutions like ClinicalTrials.gov and TRIO are increasingly being adopted by cancer centers and healthcare institutions to streamline clinical research. Observational studies are also benefiting from eClinical solutions, allowing for more efficient data collection and analysis. The Internet of Things (IoT) is playing a major role in the technology adoption, enabling real-time patient monitoring and data collection. Research funding agencies are recognizing the value of eClinical solutions and are encouraging their use in clinical research. Minor trials are also benefiting from these solutions, making clinical research more accessible and efficient for all.
The eClinical Solutions Market is experiencing significant growth due to the increasing emphasis on clinical trials and vaccine development in healthcare. With an enormous amount of data being generated in clinical research, there is a rising need for software solutions to manage this data effectively. EClinical solutions, such as TRIO and PAREXE, are gaining popularity in cancer centers, clinical research organizations (CROs), pharmaceutical companies, and academic universities. The digitization of healthcare and the Internet of Things are driving the adoption of eClinical solutions, which offer benefits like real-time access to clinical trial data, improved clinical trial processes, and increased cost efficiency. However, the lack of awareness and high costs associated with these solutions pose challenges for smaller enterprises and underdeveloped markets. The market is characterized by a firm concentration ratio, with major players like Veeva Systems dominating. Growth opportunities exist in developing and underdeveloped markets, where there is a high demand for clinical trials in chronic diseases such as diabetes, cancer, cardiovascular conditions, and infectious diseases. EClinical solutions include Clinical Trial Management Systems (CTMS), Clinical Data Management Systems (CDMS), Electronic Data Capture (EDC), and Clinical Randomization Systems. These solutions help manage clinical trial processes, supply management, site performance, and retention. The benefits of eClinical solutions include error reduction, data standardization, and improved communication between clinical researchers, healthcare providers, and academic universities. However, the adoption of these solutions requires IT infrastructure and internet connectivity, which can be a challenge in some markets. Medical devices and consultancy services are also integral to the eClinical Solutions Market, offering additional benefits like protocol matrices, drug development, and clinical research. Overall, the market is expected to continue growing as unmet medical needs and the importance of clinical trials in drug development increase.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
End-userPharmaceutical And Biotechnology CompaniesContract Research OrganizationsConsulting Service CompaniesMedical Device ManufacturersOthersDeploymentCloud-basedOn-premisesGeographyNorth AmericaEuropeAsiaRest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/eclinical-solutions-market-to-grow-by-usd-12-77-billion-2024-2028-rising-drug-clinical-trials-drive-revenue-report-highlights-ai-impact-on-trends—technavio-302322403.html
SOURCE Technavio
You may like
Technology
Cboe Global Markets Announces Increase in Share Repurchase Authorization; Declares Fourth-Quarter 2026 Dividend
Published
44 minutes agoon
October 22, 2026By
Increases share repurchase authorization by $550 millionQuarterly cash dividend of $0.86 per share
CHICAGO, Oct. 22, 2026 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today announced its Board of Directors has authorized the company to repurchase up to an additional $550 million of its outstanding common stock and declared a quarterly cash dividend of $0.86 per share of common stock for the fourth quarter of 2026.
The fourth-quarter 2026 dividend is payable on December 15, 2026, to stockholders of record as of November 30, 2026.
As of June 30, 2026, the Company had $536.8 million of availability remaining under its existing share repurchase authorizations.
“Cboe’s strong cash flow and robust balance sheet give us the flexibility to continue investing in our growth priorities while returning capital to shareholders,” said Craig Donohue, Chief Executive Officer of Cboe Global Markets. “Today’s increase to our share repurchase authorization, together with our dividend announcement, reflect the Board’s confidence in our business and our commitment to delivering long-term value.”
The share repurchase program has no expiration date. The repurchase program permits the company to purchase shares through a variety of methods, including in the open market, through established trading plans, or through privately negotiated transactions, in accordance with applicable securities laws. It does not obligate the company to make any repurchases at any specific time or situation. The timing and extent to which the company repurchases its shares will depend upon, among other things, market conditions, share price, liquidity targets, regulatory requirements and other factors. Share repurchases may be commenced or suspended at any time or from time to time without prior notice.
About Cboe Global Markets
Cboe Global Markets (Cboe: CBOE) is a leading global markets operator with a long history of innovation in equity and index derivatives. Since launching the world’s first listed options exchange in 1973, Cboe has pioneered landmark products, including the introduction of S&P 500® index options and the creation of the VIX® Index, the world’s leading gauge of market volatility, reshaping how investors manage risk and access opportunity. Today, Cboe operates derivatives, equities, and FX markets, providing trading, clearing, and investment solutions for customers worldwide. To learn more, visit www.cboe.com.
Cboe Media Contacts
Cboe Analyst Contact
Angela Tu
Tim Cave
Kenneth Hill, CFA
+1-646-856-8734
+44 (0) 7593-506-719
+1-312-786-7559
CBOE-C
CBOE-OE
Cboe®, Cboe Global Markets®, and VIX ® are registered trademarks or service marks of Cboe Exchange, Inc and S&P 500® is a registered trademark of Standard & Poor’s Financial Services LLC. All other trademarks and service marks are the property of their respective owners.
Cautionary Statements Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as “may,” “might,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.
We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price and new products and services competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our business and operational dependence on and exposure to risk from third parties; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our global operations, growth, and strategic acquisitions, wind downs, divestitures, or alliances effectively; increases in the cost of the products and services we use; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, liquidity, market, investment, counterparty, and default risks, associated with operating our clearinghouses; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing our business interests and our regulatory responsibilities; the loss of key customers or a significant reduction in trading or clearing volumes by key customers; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the accuracy of our estimates and expectations; and litigation risks and other liabilities. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made from time to time with the SEC.
We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cboe-global-markets-announces-increase-in-share-repurchase-authorization-declares-fourth-quarter-2026-dividend-302917368.html
SOURCE Cboe Global Markets, Inc.
Technology
Community Heritage Financial, Inc. Announces Adoption of Stock Repurchase Program
Published
44 minutes agoon
October 22, 2026By
MIDDLETOWN, Md., Oct. 22, 2026 /PRNewswire/ — Community Heritage Financial, Inc. (the “Company”) (OTCID: CMHF), the parent company of Middletown Valley Bank, today announced that its Board of Directors has adopted a stock repurchase program. Under the repurchase program, the Company may repurchase up to 147 thousand shares of its common stock. This amount represents approximately 5.0% of the Company’s 2.95 million shares of common stock outstanding.
The repurchase program permits shares to be repurchased from time to time on the open market, in private-negotiated transactions or otherwise. Repurchases will be made at management’s discretion at prices management considers to be attractive and in the best interests of the Company and its stockholders, subject to general market conditions, the trading price of the Company’s common stock, regulatory requirements and limitations, alternative uses for capital, the Company’s financial performance, and other factors deemed appropriate.
The repurchase program expires August 21, 2027. The repurchase program may be suspended, terminated or modified at any time for any reason and does not obligate the Company to purchase any particular number of shares.
About Community Heritage Financial, Inc.
Community Heritage Financial, Inc. is the parent company of Middletown Valley Bank (the “Bank” or “MVB”). Middletown Valley Bank offers a full suite of personal and business banking solutions, along with residential mortgage lending through its MVB Home Loans division. At the heart of the MVB brand is a commitment to delivering Absolutely Exceptional Experiences – one customer, one community, one experience at a time. Founded in 1908 in Middletown, Maryland, MVB has grown to serve customers across Frederick, Washington, and Garrett counties in Maryland, as well as Franklin County, Pennsylvania. For more information, visit www.communityheritageinc.com or www.mvbbank.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements can generally be identified by the use of forward- looking terminology such as “believes,” “expects,” “intends,” “may,” “will,” “should,” “anticipates” or similar terminology. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, changes in interest rates, stock market liquidity, deposit flows, loan demand and real estate values, as well as changes in economic, competitive, governmental, regulatory, technological and other factors which may affect the Company specifically, its existing and target market areas or the banking industry in general. The realization or occurrence of these risks or uncertainties could cause actual results to differ materially from those addressed in the forward-looking statements. The statements in this press release are made as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or results or otherwise, except as required by law.
Community Heritage Financial, Inc.
Robert E. Goetz, Jr. (“BJ”)
President & Chief Executive Officer
301-371-3055
John A. Scaldara, Jr.
Executive Vice President and Chief Financial Officer
301-371-3070
View original content to download multimedia:https://www.prnewswire.com/news-releases/community-heritage-financial-inc-announces-adoption-of-stock-repurchase-program-302917441.html
SOURCE Community Heritage Financial, Inc.
Technology
Insurance Professional Paula Miller Shares Questions to Ask Before Choosing Life Insurance in HelloNation
Published
45 minutes agoon
October 22, 2026By
The article explains how coverage needs, policy terms, premiums, exclusions, and beneficiaries can help families compare their options.
SIMI VALLEY, Calif., Oct. 22, 2026 /PRNewswire/ — What questions should you ask before choosing life insurance?
HelloNation has published an article featuring insights from Insurance Professional Paula Miller of Simi Valley, CA. The article explains how asking about coverage, costs, policy terms, and family needs can help households make informed comparisons before selecting a policy.
The HelloNation article explains that choosing life insurance begins with determining which type of policy fits a household’s goals. Term life insurance generally provides protection for a set period, while permanent policies may provide longer coverage when policy requirements are met. Understanding these differences can help narrow the available choices.
The amount of life insurance coverage is another important consideration. Income, debts, housing expenses, education plans, and dependent needs may all influence how much protection a household requires. The article notes that life insurance coverage should reflect what the policy would need to provide if the insured person died.
Coverage length should also match the household’s expected financial timeline. Term life insurance may be appropriate when protection is needed while children remain dependent, a mortgage is being paid, or retirement savings are still growing. Buyers should understand what happens when the initial term ends before selecting a policy.
The article also recommends examining life insurance premiums carefully. Age, health, coverage amount, policy type, and underwriting factors can influence cost. An insurance agent should be able to explain how these factors affect pricing and whether life insurance premiums remain level or may change over time.
Price alone, however, does not provide a complete basis for comparison. The article explains that policy exclusions, benefit terms, and coverage duration can affect the protection a policy provides. Reviewing policy exclusions before purchasing can help households understand circumstances that may limit coverage.
Beneficiaries are another important part of policy planning. Policyholders should understand how beneficiaries are named and how those selections can be changed. Marriage, divorce, births, deaths, and other significant life events may create reasons to review those decisions.
Optional policy features also deserve careful attention. Some policies include riders or other provisions designed for specific circumstances. The article recommends asking what each feature provides, what it costs, and whether it addresses a financial need relevant to the household.
The application process can affect both eligibility and final pricing. Depending on the policy, an insurer may review health information and other underwriting factors before making a final offer. An insurance agent can explain unfamiliar provisions and help applicants understand why an initial estimate may differ from final policy terms.
The article emphasizes that several factors should be evaluated together when comparing policies. Coverage amount, duration, benefits, costs, and contract terms can all affect the protection provided. Understanding these details can help families evaluate policies based on their financial responsibilities rather than monthly price alone.
Insurance needs can also change over time. Buying a home, growing a family, changing careers, or reducing debt may affect the amount or duration of protection needed. Periodically reviewing life insurance can help determine whether existing protection still reflects a household’s circumstances.
What Questions Should You Ask Before Choosing Life Insurance? features insights from Paula Miller, Insurance Professional of Simi Valley, CA, in HelloNation.
About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.
View original content to download multimedia:https://www.prnewswire.com/news-releases/insurance-professional-paula-miller-shares-questions-to-ask-before-choosing-life-insurance-in-hellonation-302917444.html
SOURCE HelloNation
Cboe Global Markets Announces Increase in Share Repurchase Authorization; Declares Fourth-Quarter 2026 Dividend
Community Heritage Financial, Inc. Announces Adoption of Stock Repurchase Program
Insurance Professional Paula Miller Shares Questions to Ask Before Choosing Life Insurance in HelloNation
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days agoBioethanol from human hair – Indian start-up’s solution to rising prices of grains and sugar
-
Technology4 days agoGMIF2026: AI Inference Powers the “Token Factory” and Drives System-Level Rethinking of Memory & Storage
-
Coin Market3 days agoWorld Liberty’s USD1 stablecoin sheds $400M in market cap in two weeks
-
Technology3 days agoInstaMall Launches Same-Day Fashion Delivery Experience, Bringing 80+ Brands to Shoppers’ Doors in Miami
-
Technology4 days agoTruecaller announces preliminary numbers for the third quarter 2026
-
Technology4 days agoSALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
-
Technology4 days agoLinktel Technologies Highlights Breakthrough 1.6T LPO Performance & Strong Market Pull at OCP 2026
-
Technology4 days agoHISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES
